193 Results

People

  1. Russo
    Russo
  2. Motzer
    Motzer
  3. Aghajanian
    Aghajanian
  4. Bajorin
    Bajorin
  5. Flombaum
    Flombaum
  6. Lichtman
    Lichtman
  7. Drilon
    Drilon
  8. Iasonos
    Iasonos
  9. Kris
    Kris
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (121)
  2. Solid Tumor Oncology Division (82)
  3. Surgery (47)
  4. Hematologic Malignancies, Division of (35)
  5. Center for Hematologic Malignancies (31)
  6. Urology (29)
  7. Genitourinary Oncology Service (27)
  8. Division of Subspecialty Medicine (23)
  9. Epidemiology and Biostatistics (22)
  10. Center for Pancreatic Cancer Research (18)
  1. "creatinine blood level"
Formats
  1. Journal Article (187)
  2. Review (3)
  3. Correspondence (1)
  4. Guidelines (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (121)
  2. Solid Tumor Oncology Division (82)
  3. Surgery (47)
  4. Hematologic Malignancies, Division of (35)
  5. Center for Hematologic Malignancies (31)
  6. Urology (29)

More Groups

People
  1. Paul Russo (19)
  2. Robert Motzer (15)
  3. Carol Aghajanian (9)
  4. Carlos Flombaum (6)
  5. Dean Bajorin (6)
  6. Ilya Glezerman (6)

More People

Years
  1. 2025 (7)
  2. 2024 (11)
  3. 2023 (8)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Gynecologic Oncology (11)
  3. Lancet Oncology (11)
  4. Cancer (9)
  5. Journal of Urology (9)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. Elsevier Science, Inc. (29)
  2. Elsevier Inc. (28)
  3. American Society of Clinical Oncology (14)
  4. Wiley Blackwell (14)
  5. Oxford University Press (13)
  6. Springer (12)

More Publishers

Results (193)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: A CCC19-registry based retrospective cohort study
    Journal Article

    Wagner, M. J.; Hennessy, C.; Beeghly, A.; French, B.; Shah, D. P.; Croessmann, S.; Vilar-Compte, D.; Ruiz-Garcia, E.; Ingham, M.; Schwartz, G. K.; more...
    Cancers (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma
    Journal Article

    Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; Park, S. H.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Pesticide use and kidney function among farmers in the Biomarkers of Exposure and Effect in Agriculture study
    Journal Article

    Shearer, J. J.; Sandler, D. P.; Andreotti, G.; Murata, K.; Shrestha, S.; Parks, C. G.; Liu, D.; Alavanja, M. C.; Landgren, O.; Beane Freeman, L. E.; more...
    Environmental Research (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Journal Article

    Lee, N. Y.; Ferris, R. L.; Psyrri, A.; Haddad, R. I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P. M. H.; Lin, J. C.; Razaq, M. A.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib in RET-altered thyroid cancers
    Journal Article

    Wirth, L. J.; Sherman, E.; Robinson, B.; Solomon, B.; Kang, H.; Lorch, J.; Worden, F.; Brose, M.; Patel, J.; Leboulleux, S.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer
    Journal Article

    Drilon, A.; Oxnard, G. R.; Tan, D. S. W.; Loong, H. H. F.; Johnson, M.; Gainor, J.; McCoach, C. E.; Gautschi, O.; Besse, B.; Cho, B. C.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save